Fox Run Management L.L.C. Makes New $788,000 Investment in Denali Therapeutics Inc. (NASDAQ:DNLI)

Fox Run Management L.L.C. purchased a new position in Denali Therapeutics Inc. (NASDAQ:DNLI) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 38,668 shares of the company’s stock, valued at approximately $788,000.

Other large investors also recently modified their holdings of the company. Quest Partners LLC bought a new stake in shares of Denali Therapeutics in the third quarter worth about $73,000. PNC Financial Services Group Inc. grew its holdings in shares of Denali Therapeutics by 30.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock worth $77,000 after buying an additional 885 shares in the last quarter. KBC Group NV grew its holdings in shares of Denali Therapeutics by 75.8% during the fourth quarter. KBC Group NV now owns 6,334 shares of the company’s stock worth $129,000 after buying an additional 2,731 shares in the last quarter. AlphaQuest LLC grew its holdings in shares of Denali Therapeutics by 177.1% during the fourth quarter. AlphaQuest LLC now owns 6,961 shares of the company’s stock worth $142,000 after buying an additional 4,449 shares in the last quarter. Finally, E Fund Management Co. Ltd. grew its holdings in shares of Denali Therapeutics by 32.2% during the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company’s stock worth $204,000 after buying an additional 2,436 shares in the last quarter. 92.92% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on DNLI shares. B. Riley reiterated a “buy” rating and set a $35.00 price objective (down from $38.00) on shares of Denali Therapeutics in a report on Wednesday, March 5th. Robert W. Baird started coverage on Denali Therapeutics in a report on Tuesday, January 7th. They set an “outperform” rating and a $31.00 price objective for the company. Oppenheimer decreased their price objective on Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating for the company in a report on Monday, March 3rd. William Blair reissued an “outperform” rating on shares of Denali Therapeutics in a research report on Friday, February 28th. Finally, The Goldman Sachs Group reduced their price target on Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Two investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $37.20.

Denali Therapeutics Stock Down 1.2 %

DNLI opened at $14.43 on Monday. Denali Therapeutics Inc. has a 12-month low of $14.01 and a 12-month high of $33.33. The stock has a market cap of $2.10 billion, a price-to-earnings ratio of -5.23 and a beta of 1.46. The business has a 50 day moving average of $19.68 and a 200-day moving average of $23.61.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.08. As a group, analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Vicki L. Sato sold 3,080 shares of Denali Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total transaction of $64,402.80. Following the completion of the sale, the director now directly owns 107,976 shares of the company’s stock, valued at approximately $2,257,778.16. This trade represents a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Ryan J. Watts sold 29,266 shares of Denali Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $20.22, for a total value of $591,758.52. Following the sale, the chief executive officer now directly owns 260,721 shares of the company’s stock, valued at approximately $5,271,778.62. The trade was a 10.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 47,940 shares of company stock valued at $973,442. Insiders own 7.90% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.